Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AB1 | P08238 | 6/20 | 1.00 |
| ▸ | CASP3 | P42574 | 6/20 | 1.00 |
| ▸ | CDC37 | Q16543 | 6/20 | 1.00 |
| ▸ | NR4A1 | P22736 | 6/20 | 0.81 |
| ▸ | TERT | O14746 | 3/20 | 0.81 |
| ▸ | PRDX1 | Q06830 | 1/20 | 0.76 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.75 |
| ▸ | CASP1 | P29466 | 1/20 | 0.75 |
| ▸ | ABHD6 | Q9BV23 | 1/20 | 0.75 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.75 |
| ▸ | TP53 | P04637 | 1/20 | 0.75 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.75 |
| ▸ | MAPT | P10636 | 1/20 | 0.75 |
| ▸ | HPGD | P15428 | 1/20 | 0.75 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.75 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.75 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.75 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.75 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.75 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.75 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18782351 | 0.92 | HSP90AB1 (0.86) | HSP90AB1CASP3CDC37NR4A1TERT | |
| SCHEMBL22011612 | 0.92 | CASP3 (0.86) | HSP90AB1CASP3CDC37NR4A1TERT | |
| SCHEMBL22011082 | 0.90 | HSP90AB1 (0.82) | HSP90AB1CASP3CDC37NR4A1TERT | |
| SCHEMBL12395123 | 0.89 | NR4A1 (1.00) | HSP90AB1CASP3CDC37NR4A1TERT | |
| SCHEMBL22010853 | 0.89 | CASP3 (0.80) | HSP90AB1CASP3CDC37NR4A1TERT | |
| SCHEMBL18782134 | 0.87 | HSP90AB1 (0.86) | HSP90AB1CASP3CDC37NR4A1TERT | |
| SCHEMBL13201839 | 0.87 | NR4A1 (0.80) | HSP90AB1CASP3CDC37NR4A1TERT | |
| SCHEMBL20371640 | 0.86 | NR4A1 (0.84) | HSP90AB1CASP3CDC37NR4A1TERT | |
| SCHEMBL22011610 | 0.86 | NR4A1 (0.81) | HSP90AB1CASP3CDC37NR4A1TERT | |
| SCHEMBL18781835 | 0.86 | TERT (0.77) | HSP90AB1CASP3CDC37NR4A1TERT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11753436-B2 | Analogs of celastrol | ERX PHARMACEUTICALS CORPORATION (US) | 2023-09-12 | — | — | US | disclosed |
| US-11753436-B2 | Analogs of celastrol | ERX PHARMACEUTICALS CORPORATION (US) | 2023-09-12 | — | — | US | disclosed |
| US-20210061851-A1 | ANALOGS OF CELASTROL | ERX PHARMACEUTICALS CORPORATION | 2021-03-04 | — | — | US | disclosed |
| US-10808005-B2 | Ligand for orphan nuclear receptor Nur77 and uses thereof | IXMEDICINE (XIAMEN) BIOLOGICAL TECHNOLOGY COMPANY LIMITED (CN) | 2020-10-20 | — | — | US | disclosed |
| US-10662218-B2 | Analogs of celastrol | ERX PHARMACEUTICALS CORPORATION | 2020-05-26 | — | — | US | disclosed |
| US-20190330261-A1 | LIGAND FOR ORPHAN NUCLEAR RECEPTOR NUR77 AND USES THEREOF | XIAMEN UNIVERSITY (CN) | 2019-10-31 | — | — | US | disclosed |
| EP-3480207-A1 | ORPHAN NUCLEAR RECEPTOR NUR77 LIGAND AND APPLICATION THEREOF | Xiamen University (CN) | 2019-05-08 | — | — | EP | disclosed |
| US-20110166216-A1 | Compositions and Methods for Inhibiting Growth and Metastasis of Melanoma | BURNHAM INSTITUTE FOR MEDICAL RESEARCH | 2011-07-07 | — | — | US | disclosed |
| US-7888355-B2 | Compositions and methods for inhibiting growth and metastasis of melanoma | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2011-02-15 | — | — | US | disclosed |
| US-20100305129-A1 | COMPOSITIONS AND METHODS FOR INHIBITING GROWTH AND METASTASIS OF MELANOMA | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-12-02 | — | — | US | disclosed |
| US-7776894-B2 | Compositions and methods for inhibiting growth and metastasis of melanoma | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2010-08-17 | — | — | US | disclosed |
| WO-2009026163-A1 | COMPOSITIONS AND METHODS FOR INHIBITING GROWTH AND METASTASIS OF MELANOMA | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-02-26 | — | — | WO | disclosed |
| US-20090054438-A1 | COMPOSITIONS AND METHODS FOR INHIBITING GROWTH AND METASTASIS OF MELANOMA | BURNHAM INSTITUTE FOR MEDICAL RESEARCH (US) | 2009-02-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210061851-A1 | ANALOGS OF CELASTROL | GIPR, GPR119, EBP | HSP90AB1 191/4885CASP3 247/4885CDC37 310/4885 |
| US-10808005-B2 | Ligand for orphan nuclear receptor Nur77 and uses thereof | NR2E3, NR0B1, NR0B2 | HSP90AB1 2423/4885CASP3 4286/4885CDC37 3351/4885 |
| US-20100305129-A1 | COMPOSITIONS AND METHODS FOR INHIBITING GROWTH AND METASTASIS OF MELANOMA | API5, ACIN1, MCL1 | HSP90AB1 116/4885CASP3 16/4885CDC37 732/4885 |
| US-10662218-B2 | Analogs of celastrol | GIPR, GPR119, EBP | HSP90AB1 191/4885CASP3 247/4885CDC37 310/4885 |
| US-11753436-B2 | Analogs of celastrol | GIPR, GPR119, EBP | HSP90AB1 191/4885CASP3 247/4885CDC37 310/4885 |
| US-20190330261-A1 | LIGAND FOR ORPHAN NUCLEAR RECEPTOR NUR77 AND USES THEREOF | NR2E3, NR0B1, NR0B2 | HSP90AB1 2423/4885CASP3 4286/4885CDC37 3351/4885 |
| US-20090054438-A1 | COMPOSITIONS AND METHODS FOR INHIBITING GROWTH AND METASTASIS OF MELANOMA | API5, ACIN1, MCL1 | HSP90AB1 116/4885CASP3 16/4885CDC37 732/4885 |
| US-20110166216-A1 | Compositions and Methods for Inhibiting Growth and Metastasis of Melanoma | API5, ACIN1, MCL1 | HSP90AB1 116/4885CASP3 16/4885CDC37 732/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.